PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

Usefulness of UroVysion test in diagnostics of bladder cancer
Article published in Urologia Polska 2006/59/4.

authors

Aleksandra Binka-Kowalska, Maria Constantinou, Bogdan Kałużewski
Zakład Genetyki Medycznej Uniwersytetu Medycznego w Łodzi

keywords

bladder, bladder cancer, UroVysion test, chromosome aberrations, non-invasive diagnostics, bladder cancer recurrences

summary

Cystoscopy is the standard method of primary and recurrent bladder cancer diagnosis. Standard cytology has been regarded as an additional diagnostic tool to select patients for cystoscopic evaluation. However, numerous studies have demonstrated that cytology has high specificity but poor sensitivity for bladder cancer detection. In response to that, several attempts have been made to improve the detection of cancer cells in urinary samples.
Fluorescence in situ hybridization (FISH) is a rapid and powerful technique to detect cells with numerical or structural chromosome aberrations indicative of malignancy. Recently, a multitarget, multicolor FISH assay containing centromeric probes to chromosomes 3, 7, and 17 and a locus-specific probe to band 9p21 has been shown to have high sensitivity and specificity for the detection of bladder cancer in urine specimens. By using UroVysion test we were able to detect almost all invasively growing tumors including those with infiltration restricted to subepithelial connective tissue (pT1). FISH also identified a large fraction of the noninvasive bladder tumors (pTa). UroVysion test is useful for predicting the recurrence of bladder cancer, particularly high grade or high stage tumors. Patients with a negative urine FISH results are at low risk for early recurrence and might be candidates for a reduced frequency of follow-up cystoscopies. FISH analysis does not appear to be affected by inflammation. Bacillus Calmette-Guerin (BCG) intravesical treatment does not appear to affect the interpretability of FISH. Monitoring of BCG treated patients with FISH may help detect earlier recurrences (or persistence) of bladder cancer.

references

  1. Didkowska J, Wojciechowska U, Tarnowski W, Zatoński W: Nowotwory złośliwe w Polsce w 1999 roku. Centrum Onkologii - Instytut im. M. Skłodowskiej-Curie. Zakład Epidemiologii i Prewencji Nowotworów. Warszawa 2002, 15-37.
  2. Lamm DL, Torti FM: Bladder Cancer, 1996. Ca Cancer J Clin 1996, 46, 2, 93-112.
  3. Szeszenia-Dąbrowska N, Strzelecka A, Wilczyńska U, Szymczak W: Nowotwory pochodzenia zawodowego w Polsce w latach 1971-1994. Med Pr 1997, 1, 1-14.
  4. Glas AS, Roos D, Deutekom M et al: Tumor markers in the diagnosis of primary bladder cancer. A systematic review. J Urol 2003, 169 (6), 1975-1982.
  5. Lamb D: Correlation of chromosome counts with histological appearances and prognosis in transitional-cell carcinoma of bladder. Br Med J 1967, 4, 1 (535): 273-277.
  6. Hopman AH, Moesker O, Smeets AW et al: Numerical chromosome 1, 7, 9, and 11 aberrations in bladder cancer detected by in situ hybridization. Cancer Res 1991, 15, 51 (2), 644-651.
  7. Sandberg AA, Berger CS: Review of chromosome studies in urological tumors. II. Cytogenetics and molecular genetics of bladder cancer. J Urol 1994, 151 (3), 545-560.
  8. Marano A, Pan Y, Li C et al: Chromosomal numerical aberrations detected by fluorescence in situ hybridization on bladder washings from patients with bladder cancer. Eur Urol 2000, 37 (3), 358-365.
  9. Czerniak B, Li L, Chaturvedi V: Genetic modeling of human urinary bladder carcinogenesis. Genes Chromosomes Cancer 2000, 27 (4), 392-402.
  10. Fadl-Elmula I, Gorunova L, Mandahl N: Karyotypic characterization of urinary bladder transitional cell carcinomas. Genes Chromosomes Cancer 2000, 29 (3), 256-265.
  11. Muscheck M, Sukosd F, Pesti T, Kovacs G: High density deletion mapping of bladder cancer localizes the putative tumor suppressor gene between loci D8S504 and D8S264 at chromosome 8p23.3. Lab Invest 2000, 80 (7), 1089-1093.
  12. Yu DS, Chen HI, Chang SY: Chromosomal aberrations in transitional cell carcinoma: its correlation with tumor behavior. Urol Int 2002, 69 (2), 129-135.
  13. Pycha A, Mian C, Haitel A et al: Fluorescence in situ hybridization identifies more aggressive types of primarily noninvasive (stage pTa) bladder cancer. J Urol 1997, 157 (6), 2116-2119.
  14. Jung I, Reeder JE, Cox C: Chromosome 9 monosomy by fluorescence in situ hybridization of bladder irrigation specimens is predictive of tumor recurrence. J Urol 1999, 162 (6), 1900-1903.
  15. Eleuteri P, Grollino MG, Pomponi D, De Vita R: Chromosome 9 aberrations by fluorescence in situ hybridization in bladder transitional cell carcinoma. Eur J Cancer 2001, 37, 1496-1503.
  16. Watters AD, Ballantyne SA, Going JJ et al: Aneusomy of chromosomes 7 and 17 predicts the recurrence of transitional cell carcinoma of the urinary bladder. BJU Int 2000, 85, 42-47.
  17. Bartlett JM, Adie L, Watters ADet al: Chromosomal aberrations in transitional cell carcinoma that are predictive of disease outcome are independent of polyploidy. BJU Int 1999, 84 (7): 775-779.
  18. Ishiwata S, Takahashi S, Homma Y et al: Noninvasive detection and prediction of bladder cancer by fluorescence in situ hybridization analysis of exfoliated urothelial cells in voided urine. Urology 2001, 57, 811-815.
  19. Eleuteri P, Grollino MG, Pomponi D et al: Bladder transitional cell carcinomas: a comparative study of washing and tumor bioptic samples by DNA Flow Cytometry and FISH analyses. Eur Urol 2000, 37, 275-280.
  20. Kimura F, Florl AR, Seifert HH et al: Destabilization of chromosome 9 in transitional cell carcinoma of the urinary bladder. Br J Cancer 2001, 14, 85 (12), 1887-1893.
  21. Berggren P: Molecular changes in the tumour suppressor genes p53 and CDKN2A/ARF in human urinary bladder cancer. KONGHL Carolinska Medico Chirurgiska Institutet, Stockholm 2002, 1-13.
  22. Stadler WM, Steinberg G, Yang X et al: Alterations of the 9p21 and 9q33 chromosomal bands in clinical bladder cancer specimens by fluorescence in situ hybridization. Clin Cancer Res 2001, 7 (6), 1676-1682.
  23. Edwards J, Duncan P, Going JJ et al: Identification of loci associated with putative recurrence genes in transitional cell carcinoma of the urinary bladder. J Pathol 2002, 196 (4), 380-385.
  24. Sokolova IA, Halling KC, Jenkins RB et al: The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2000, 2 (3), 116-123.
  25. Bubendorf L, Grilli B, Sauter G et al: Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol 2001, 116, 79-86.
  26. Placer J, Espinet B, Salido M et al: Clinical Utility of a Multiprobe FISH Assay in Voided Urine Specimens for the Detection of Bladder Cancer and its Recurrences, Compared with Urinary Cytology. Eur Urol 2002, 42 (6), 547-552.
  27. Halling KC, King W, Sokolova IA et al: A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assay for the detection of urothelial carcinoma in urine. J Urol 2002, 167, 2001-2006.
  28. Sarosdy MF, Schellhammer P, Bokinsky G et al: Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 2002, 168 (5): 1950-1954.
  29. Dalquen P, Kleiber B, Grilli B et al: DNA image cytometry and fluorescence in situ hybridization for noninvasive detection of urothelial tumors in voided urine. Cancer 2002, 25, 96 (6), 374-379.
  30. Skacel M, Fahmy M, Brainard JA et al: Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 2003, 169 (6), 2101-2105.
  31. Halling KC, King W, Sokolova IA et al: A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 2000, 164 (5), 1768-1775.
  32. Abbott Labs Conferences; Molecular Insights in Bladder Cancer Recurrence. Speakers: Steven M. Anderson, Ph. D., Kevin C. Halling, M. D., Ph. D., Michael F. Sarosdy, M. D.
  33. Takahashi T, Lohse C, Pankratz VS et al: Predicting urothelial carcinoma recurrence with fluorescence in situ hybridization analysis of urine. The American Urological Association (AUA) ´s Annual Meeting 2002; Abstract ID: 100351.
  34. Mack D, Frick J: Diagnostic problems of urine cytology on initial follow-up after intravesical immunotherapy with Calmette-Guerin bacillus for superficial bladder cancer. Urol Int 1994, 52 (4), 204-207.
  35. Karnes RJ, Halling KC, Lieber MM: Urine fluorescence in situ hybridization analysis during Baciilus Calmette-Guerin treatments in urothelial carcinoma. AUA Poster 1005, 2003, Abstract.
  36. Kruger S, Mess F, Bohle A, Feller AC: Numerical aberrations of chromosome 17 and the 9p21 locus are independent predictors of tumor recurrence in non-invasive transitional cell carcinoma of the urinary bladder. Int J Oncol 2003, 23 (1), 41-48.

correspondence

Aleksandra Binka-Kowalska
Zakład Genetyki Medycznej UM
ul. Sterlinga 1/3
91-425 Łódź
tel. (042) 632 70 02
genetyka@csk.am.lodz.pl